Chippenham-based drug development firm Vectura today strengthened its position in the respiratory diseases treatment market with the €130m (£108m) acquisition of specialist German pharmaceutical company Activaero. Privately-owned Activaero’s proprietary smart nebuliser-based technology targets drugs at particular areas of the lung. It is currently part in seven clinical and several pre-clinical stage programmes. Vectura, which...